Advanced Human Acellular
Dermal Matrix
ABOUT
Dermacell AWM is a technologically advanced human acellular dermal matrix that is decellularized using Matracell®, a proprietary, patented, and validated processing technology.
Matracell removes a minimum of 97% of donor DNA, allowing for rapid cellular infiltration and re-vascularization. Dermacell is utilized for the treatment of chronic wounds as well as burn management and for soft tissue reconstructive procedures such as breast reconstruction.
TWO PHYSICALLY DISTINCT SIDES
Reticular (Dermal)
Lighter in Appearance, Larger Pores, Absorbs Blood
Papillary (Basement Membrane)
Duller with Smaller Pores, Repels Blood
Clinical Tip
When applied, the reticular side is placed against the surgical wound or the most vascularized tissue.
TWO PHYSICALLY DISTINCT CONFIGURATIONS
Product Features
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec
ullamcorper mattis, pulvinar dapibus leo.
Intact Acellular Framework:
Retains native growth factors, collagen and elastin
Room Temperature
Ready to use out of the package (15°C - 30°C)
Bio-hospitable:
All cells ≥ 97% donor DNA removed to potentially minimize any adverse patient response
Strength:
Pull-out strength and load to failure are comparable to native dermis
Sterility:
Sterilized to a Sterility Assurance Level (SAL) of 10-6, medical device grade sterility
Structural Support:
Facilitates use with sutures, staples
Proven Efficacy:
Conducted the largest randomized controlled trial (RCT) to date using hADM in chronic wounds
Tensile Strength:
Demonstrated ultimate tensile strength of 635.4 + 199.9N
Suture Strength:
As per biochemical testing the suture retention strength is 134.6 + 55.1N
MATRACELL DECELLULARIZATION TECHNOLOGY
Matracell gently renders allografts acellular without compromising the biomechanical
or biochemical properties, growth factors, collagen, and elastinthat supports patient healing.
STEP - 01
Decellularization
STEP - 02
Rinsing
STEP - 03
Preservation
STEP - 04
Sterilization
USAGE INFORMATION
durch Humor oder zufällige Wörter welche.
Would Bed Preparation
Proper wound bed preparation is vital to successful wound healing, If the wound bed is not properly prepared, Dermacell AWM may not integrate as intended.
Dermacell AWM Application
Ensure hemostasis has occurred prior to the application of Dermacell AWM. If mild bleeding is present, apply pressure for 10 minutes before applying Dermacell AWM. If unable to achieve hemostasis, apply compression dressings and have the patient return the following week for application of Dermacell AWM.
Apply Dermacell AWM with the reticular side against the wound bed using aseptic/sterile technique.
Ensure intimate contact is maintained between the wound bed and Dermacell AWM by gently pushing it towards the middle of the wound. (The edges of Dermacell AWM can be trimmed to meet the perimeter of the wound bed or overlap the wound margin by a few millimeters.
Dermacell AWM Fixation
Dermacell AWM should be secured to the wound bed with sutures, staples or SteriStrips to ensure Dermacell AWM remains in contact with the wound bed.
Dermacell AWM
Top Dressing Application
Cover Dermacell with a non-adherent primary dressing, bolster and/or padding, particularly if the wound has moderate to heavy exudate.
The primary dressing should be secured with an outer wrap a.k.a. secondary dressing because it not only secures the primary dressing, but acts as a protectant for the graft too.
FIELDS OF APPLICATION
Dermacell AWM has demonstrated applicability in a variety of medical procedures, including chronic wounds, traumatic wounds, injuries and surgical reconstruction.
Dermacell AWM is able to be applied to any non-healing wound, including application over exposed tendon or bone.
FAQ’s
- HIV-1/2 antibody & HIV antigen
- Hepatitis B surface antigen
- Hepatitis B core antibody
- Hepatitis C antibody
- Syphilis
- Malaria
- HTLV I & II antibody
- CMV IgG
No, each product is for single use only.
Each product is for single patient use only.
The products can be stored in a clean, dry environment at ambient room temperature (15-30C). There is no need for refrigeration or freezing.
No, our products do not contain any live cells.
No, our products are non-immunogenic.
- Proprietary processing using patented Matracell technology (97% donor DNA is removed) and validated sterilization methods, patented PRESERVON technology (SAL 10-6) are used to eliminate potential deleterious components of the allograft.
- The chances of graft rejection or infection is one in the million.
- However, the product should be used with caution in patients with a known intolerance towards Ofloxacin, Vancomycin, and Amphotericin B antibiotics
- Greater than or equal to 97% of DNA removed
- Intact acellular framework
- Structural support for cells
- 10-6 sterility assurance level
- Room temperature storage
- Ready-to-use
- The distributor, intermediary and/or end-user clinician or facility is responsible for storing decellularized dermis under appropriate conditions prior to further distribution or implantation. Dermis must be stored at room temperature (15°C to 30°C).
- Do not freeze or refrigerate.
- Minimize excessive exposure to light and protect from excessive heat.
Complications can occur because of various factors:
- Infection – Remove DermACELL, control the infection and apply a new matrix following adequate wound bed preparation
- Detached or displaced matrix – Remove DermACELL and assess to establish the reasons for failure. Perform adequate wound bed preparation before applying a new matrix.
- Excessive inflammation/allergic reaction – Remove DermACELL and do not reapply a new matrix.
- Failure to heal/lack of effect – Reassess the wound and the patient. When the wound is not healing the matrix may be displaced and there may be an increase in wound size.
Acellular dermal matrix meshing reduces rates of postoperative seroma, hematoma, and infection and decreases drain removal time compared with non-meshed acellular dermal matrix.